ARGA Investment Management LP purchased a new stake in shares of InMode Ltd. (NASDAQ:INMD - Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 31,571 shares of the healthcare company's stock, valued at approximately $456,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. LSV Asset Management lifted its position in InMode by 17.2% during the first quarter. LSV Asset Management now owns 2,010,367 shares of the healthcare company's stock valued at $35,664,000 after purchasing an additional 295,296 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of InMode by 234.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,123,756 shares of the healthcare company's stock valued at $19,935,000 after buying an additional 788,157 shares in the last quarter. Systematic Financial Management LP raised its stake in InMode by 2.2% during the first quarter. Systematic Financial Management LP now owns 1,049,608 shares of the healthcare company's stock valued at $18,620,000 after buying an additional 22,785 shares during the last quarter. DDD Partners LLC lifted its stake in shares of InMode by 63.1% in the first quarter. DDD Partners LLC now owns 989,903 shares of the healthcare company's stock worth $17,561,000 after buying an additional 382,938 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its position in shares of InMode by 6.6% during the first quarter. Acadian Asset Management LLC now owns 556,413 shares of the healthcare company's stock valued at $9,858,000 after buying an additional 34,623 shares during the last quarter. Hedge funds and other institutional investors own 68.04% of the company's stock.
InMode Stock Performance
INMD opened at $15.48 on Friday. InMode Ltd. has a one year low of $13.14 and a one year high of $19.85. The stock has a market capitalization of $978.48 million, a PE ratio of 6.27 and a beta of 2.09. The business's 50 day moving average price is $15.01 and its 200 day moving average price is $14.66.
InMode (NASDAQ:INMD - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The healthcare company reported $0.47 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.03). InMode had a net margin of 44.50% and a return on equity of 18.38%. The company had revenue of $95.60 million during the quarter, compared to analysts' expectations of $98.45 million. During the same quarter in the previous year, the business posted $0.34 EPS. The business's quarterly revenue was up 10.6% compared to the same quarter last year. As a group, equities research analysts forecast that InMode Ltd. will post 1.75 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of equities analysts recently commented on the company. Canaccord Genuity Group raised their target price on InMode from $14.00 to $16.00 and gave the stock a "hold" rating in a report on Friday, October 10th. Needham & Company LLC reissued a "hold" rating on shares of InMode in a research note on Friday, October 10th. Wall Street Zen raised InMode from a "hold" rating to a "buy" rating in a research note on Saturday, October 18th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of InMode in a research report on Wednesday, October 8th. Finally, Barclays reduced their target price on InMode from $24.00 to $21.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 30th. One equities research analyst has rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $16.85.
Get Our Latest Analysis on InMode
InMode Profile
(
Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
